TexMACS™ GMP Medium

TexMACS GMP Medium is specialized for optimal cultivation of human T cells and Treg cells. It is manufactured without animal-derived components. TexMACS GMP Medium is either filled in bottles or flexible bags, making handling in GMP confirming processes easy.

Choose your product:

Related products for TexMACS™ GMP Medium

Specifications for TexMACS™ GMP Medium
Overview

TexMACS GMP Medium is specialized for optimal cultivation of human T cells and Treg cells. It is manufactured without animal-derived components. TexMACS GMP Medium is either filled in bottles or flexible bags, making handling in GMP confirming processes easy.

Detailed product information
Background information

TexMACS GMP Medium is serum- and xeno-component free.

  • Pharmaceutical grade human serum albumine
  • Optimized formulation containing glucose and stable glutamine (L-alanyl-L-glutamine)
  • QC functionality test on every batch
  • Flexible bags (2000 mL) – without phenol red
  • Bottles (1000 mL) – with and without phenol red
Applications

TexMACS GMP Medium has been developed for the cultivation and expansion of human T cells and Treg cells, and optimized for the use in combination with the CliniMACS Cytokine Capture System (IFN-gamma).

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Disclaimer

MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.

Product data and images for TexMACS™ GMP Medium
Figure 1

TexMACS GMP Medium

Figure 2

TexMACS GMP Medium 1000 mL bottle

Figure 3

Superb polycloncal activation/expansion of human T cell. Comparison of expansion rates of human T cells with TexMACS Medium, a competitor product, and serum-containing basal medium (RPMI + 10% FBS) after 14 days of expansion using the T Cell Activation/Expansion Kit, human.

Citations for TexMACS™ GMP Medium
Publications
  1. Schwarze, L. I. et al. (2021) Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients. Gene Ther. 28 (9): 572-587
  2. Fraser, A. R. et al. (2017) Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis. Cytotherapy 19 (9): 1113-1124
  3. Tischer, S. et al. (2014) Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells. J. Transl. Med. 12: 336
  4. Fernández, L. et al. (2019) GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy. Front Immunol 10 (10): 2361
  5. Priesner, C. et al. (2016) Comparative analysis of clinical-scale IFN-γ-positive T cell enrichment using partially and fully integrated platforms. Front Immunol 7: 393
  6. Fraser, H. et al. (2018) A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. Mol Ther Methods Clin Dev. 31649672 (8): 198-209
  7. Bernaldo-de-Quirós, E. et al. (2022) A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy. Front Immunol 16 (13): 893576
  8. Glienke, W. et al. (2022) GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18. Front Immunol 24 (13): 839783
  9. Cooper, R. S. et al. (2021) Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19. Front Immunol 11: 598402
  10. Lavazza, C. et al. (2022) Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product. J. Transl. Med. 20 (1): 14
  11. Joedicke, J. J. et al. (2021) Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. Mol Ther Methods Clin Dev. 25 (24): 181-198

You have previously chosen International as your location.
What do you want to do?